Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 30‑Month Interim Analysis of Post‑marketing Surveillance
Neurology and Therapy · 2025-12 · 14 (6) · 2429-2451
DOI: 10.1007/s40120-025-00799-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurology and Therapy, online erschienen am 26.09.2025. Verfasst von Takashi Yamamura und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, National Institute of Neuroscience, National Centre of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo, 187-8…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chugai Pharmaceutical Co., Ltd..
Abstract (Originalsprache)
INTRODUCTION: A large-scale post-marketing surveillance (PMS) study is ongoing to evaluate the safety and effectiveness of satralizumab over 6 years in Japanese patients with neuromyelitis optica spectrum disorder (NMOSD) in real-world settings. We present the results of a 30-month interim analysis of the study. METHODS: This PMS is being conducted across 234 sites in Japan. In this 30-month interim analysis, the end of the observation period was defined as either the date of data lock for the 30-month case report form for all patients or the last observation date for patients with satralizumab discontinuation. Primary outcomes include proportion of patients experiencing adverse drug reactions (ADRs), event rate, and oral glucocorticoid use. Secondary outcomes include time to relapse and relapse rate. RESULTS: Of 571 patients included (mean age: 52.4 years), 91.76% were female. At baseline, 85.98% of patients received oral glucocorticoids. ADRs were reported in 28.72% of patients (event rate: 27.69 events/100 person-years), with infections being most common (11.73%; 8.97 events/100 person-years). Univariate analysis showed that at 30 months, serious infections occurred in 6.83% of patients (5.00 events/100 person-years vs 8.13 events/100 person-years during 0-6 months) and were more frequent in patients aged ≥ 75 years, with diagnosis-to-treatment initiation duration ≥ 10 years, ≥ 3 relapses within 2 years, and Expanded Disability Status Scale score ≥ 6. Mean glucocorticoid dose decreased from 12.27 mg/day (baseline) to 3.48 mg/day (30 months). Kaplan-Meier cumulative relapse-free rate was 85.86% at 30 months. The annualized relapse rate was 0.08/person-year. Overall, 9.63% and 3.50% of patients discontinued treatment because of adverse events and relapses, respectively. CONCLUSION: Serious infections were more common during the satralizumab treatment period, occurring most frequently within the first 6 months, highlighting the need for continuous monitoring of infections throughout satralizumab treatment. Satralizumab was found to be safe, without new safety concerns over 30 months. A reduction in concomitant immunosuppressive therapy usage was observed. The study demonstrated the effectiveness of satralizumab in preventing relapses in Japanese patients with NMOSD. TRIAL REGISTRATION: UMIN Clinical Trials Registry, UMIN000041047.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Immunology, National Institute of Neuroscience, National Centre of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo, 187-8511, Japan. yamamura@ncnp.go.jp.
- Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
- Department of Neurology, Brain Research Institute, Niigata University, Niigata, 951-8585, Japan.
- Medical Education Center, Niigata University School of Medicine, Niigata, 951-8510, Japan.
- Department of Neurology, Tokyo Metropolitan Ebara Hospital, Tokyo, 145-0065, Japan.
- Department of Clinical Research, National Hospital Organization Hokkaido Medical Center, Sapporo, 063-0005, Japan.
Förderung
- Chugai Pharmaceutical Co., Ltd.
Zitieren
APA
Yamamura, T., Isobe, N., Kawachi, I., Nohara, C., Miyazaki, Y., Tomita, M., Kamei, Y., Yamashita, K., Nakahara, J., Nakashima, I., & Fujihara, K. (2025). Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 30‑Month Interim Analysis of Post‑marketing Surveillance. Neurology and Therapy, 14(6), 2429-2451. https://doi.org/10.1007/s40120-025-00799-7
Vancouver
Yamamura T, Isobe N, Kawachi I, Nohara C, Miyazaki Y, Tomita M, et al. Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 30‑Month Interim Analysis of Post‑marketing Surveillance. Neurology and Therapy. 2025;14(6):2429-2451. doi:10.1007/s40120-025-00799-7
BibTeX
@article{Yamamura2025,
author = {Yamamura, Takashi and Isobe, Noriko and Kawachi, Izumi and Nohara, Chiyoko and Miyazaki, Yusei and Tomita, Minami and Kamei, Yuta and Yamashita, Katsuhisa and Nakahara, Jin and Nakashima, Ichiro and Fujihara, Kazuo},
title = {Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 30‑Month Interim Analysis of Post‑marketing Surveillance},
journal = {Neurology and Therapy},
year = {2025},
volume = {14},
number = {6},
pages = {2429--2451},
doi = {10.1007/s40120-025-00799-7}
}
EUVIMED